CINECA IRIS Institutional Research Information System

VALERIO, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.276
EU - Europa 1.888
AS - Asia 345
AF - Africa 129
SA - Sud America 16
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.659
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.236
IT - Italia 658
DE - Germania 410
SE - Svezia 335
GB - Regno Unito 140
CN - Cina 131
BG - Bulgaria 129
AT - Austria 121
CI - Costa d'Avorio 75
VN - Vietnam 50
SN - Senegal 40
IN - India 38
SG - Singapore 35
TR - Turchia 30
CA - Canada 29
RU - Federazione Russa 20
HK - Hong Kong 18
BE - Belgio 16
JP - Giappone 16
PL - Polonia 11
FI - Finlandia 9
FR - Francia 7
GR - Grecia 7
NL - Olanda 7
CR - Costa Rica 6
IR - Iran 6
UA - Ucraina 6
BR - Brasile 5
KR - Corea 5
MA - Marocco 5
AU - Australia 4
PH - Filippine 4
PK - Pakistan 4
CH - Svizzera 3
EC - Ecuador 3
EG - Egitto 3
ID - Indonesia 3
MX - Messico 3
NG - Nigeria 3
BH - Bahrain 2
CL - Cile 2
IE - Irlanda 2
IL - Israele 2
PE - Perù 2
SV - El Salvador 2
VE - Venezuela 2
ZA - Sudafrica 2
A1 - Anonimo 1
AR - Argentina 1
CO - Colombia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
MT - Malta 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.659
Salva come PNG Salva come JPEG
Città #
Chandler 323
Milan 292
Fairfield 258
Woodbridge 169
Ashburn 158
Houston 142
Sofia 129
Seattle 126
Wilmington 121
Vienna 99
Cambridge 96
Abidjan 75
New York 72
Princeton 72
Ann Arbor 66
London 52
Beijing 51
Lawrence 51
Dakar 40
Florence 39
Medford 38
Frankfurt am Main 36
Rome 36
Redwood City 30
Serra 30
Boulder 29
Dong Ket 25
Pisa 23
Dearborn 22
Redmond 22
Bremen 21
San Diego 21
Ottawa 20
Washington 18
Des Moines 17
Hong Kong 16
Brussels 15
Scandicci 12
Chiesina Uzzanese 10
Izmir 9
Hefei 8
Lancaster 8
Nanchang 8
Nanjing 8
Tianjin 7
Tokyo 7
Amsterdam 6
Kocaeli 6
Salt Lake City 6
San José 6
Shanghai 6
Shenyang 6
Istanbul 5
Jiaxing 5
Ningbo 5
Norwalk 5
Phoenix 5
Samsun 5
Urmia 5
Zhengzhou 5
Duncan 4
Edinburgh 4
Jinan 4
Montreal 4
Napoli 4
Toronto 4
Atakum 3
Bangalore 3
Cleveland 3
Hatfield 3
Hebei 3
Jakarta 3
Kunming 3
Lagos 3
Los Angeles 3
Mumbai 3
Munich 3
Stuttgart 3
Vicopisano 3
Angri 2
Bari 2
Baton Rouge 2
Bientina 2
Bologna 2
Boydton 2
Calcinaia 2
Campiglia Marittima 2
Cellole 2
Changsha 2
Crick 2
Dublin 2
Epsom 2
Geneva 2
Genoa 2
Gurgaon 2
Haikou 2
Hyderabad 2
Islamabad 2
Johannesburg 2
Konandai 2
Totale 3.108
Salva come PNG Salva come JPEG
Nome #
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 171
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 160
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 152
Targeted Therapy in Thyroid Cancer: State of the Art 146
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 141
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 140
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 140
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 135
mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases 130
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 127
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 127
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 123
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer 122
Il carcinoma tiroideo: nuove prospettive terapeutiche. 120
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 120
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 120
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 115
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 109
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 105
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 103
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 103
DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER 102
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 100
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 97
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 96
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 95
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 88
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 87
null 84
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 83
Role of oxidative stress in radio-induced DNA damage and in RET/PTC rearrangement in papillary thyroid cancer 79
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 78
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 76
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 71
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 66
Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study 64
Re: "Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem" by Nervo et al 63
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 62
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 59
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 57
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 57
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 55
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 53
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 46
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 45
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer 45
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 43
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 41
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 38
FDG-PET/CT Correlates with the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival 36
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 33
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 32
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 30
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 13
Enlargement of a metastatic lymph node from differentiated thyroid cancer after COVID-19 vaccination 7
Totale 4.790
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.642
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.642
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019257 0 0 0 0 0 8 36 14 28 40 76 55
2019/20201.109 65 69 85 91 111 127 124 77 98 92 149 21
2020/2021471 59 20 59 14 18 76 19 28 35 40 31 72
2021/2022607 16 14 14 25 132 83 14 27 39 37 46 160
2022/20231.279 162 187 90 89 110 124 40 108 238 19 94 18
2023/2024711 104 122 139 91 147 108 0 0 0 0 0 0
Totale 4.790